1. |
|
|
2. |
|
|
3. |
- Ahlman, Håkan, 1947, et al.
(författare)
-
En "ny" tumörmarkör.
- 1996
-
Ingår i: Klinisk Kemi i Norden, 8.. - Göteborg. ; , s. 45-52
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
4. |
|
|
5. |
|
|
6. |
- Olausson, Michael, 1956, et al.
(författare)
-
[Liver transplantation in neuroendocrine tumors prolongs symptom-free period, might also be a cure]. : Levertransplantation vid neuroendokrina tumörer. Ger längre tids symtomfrihet, kanske även bot.
- 1999
-
Ingår i: Läkartidningen. - 0023-7205. ; 96:36, s. 3783-6
-
Tidskriftsartikel (refereegranskat)abstract
- Several neuroendocrine tumours, such as carcinoids and pancreatic endocrine tumours, may manifest relatively slow tumour growth. The patients may suffer from severe hormonal symptoms, largely due to liver metastases which sometimes are amenable to cytoreductive surgery. If residual tumour after primary tumour resection is multilobar, liver transplantation may be one way to treat hormonal symptoms and possibly prolonging survival. Early long-term outcome of liver transplantation in patients with neuroendocrine tumours suggests prognosis to be more favourable for carcinoids than for endocrine pancreatic tumours. It is suggested that liver transplantation may be appropriate for patients with isolated hepatic tumour disease in the following situations: 1, tumour recurrence after liver surgery for cure; 2, non-resectable liver disease, especially in cases of severe hormonal symptoms; and 3, disease progression after hepatic arterial embolisation and medical therapy. These indications are discussed in the light of three case reports.
|
|
7. |
|
|
8. |
|
|
9. |
- Eriksson, Mikael, et al.
(författare)
-
Klinisk stadieindelning
- 1998
-
Ingår i: Onkologi. - 9147048581 ; , s. 75-79
-
Bokkapitel (refereegranskat)
|
|
10. |
- Henic, E, et al.
(författare)
-
Nytt behandlingsprogram vid avancerad ovarialcancer. Tillfredsställande resultat med decentraliserad cytostatikaterapi
- 1998
-
Ingår i: Läkartidningen. - 0023-7205. ; 95:22, s. 8-2574
-
Tidskriftsartikel (refereegranskat)abstract
- A trial of decentralised cytostatic (carboplatin + cyclophosphamide) treatment of advanced ovarian cancer under centralised supervision, carried out in the southern health care region, yielded good results. As carboplatin and cyclophosphamide cause myelosuppression which is commonly most manifest two weeks after treatment, increasing dosage intervals and reducing dosages is often necessary. However, compliance with the protocol for increasing dosage intervals and reducing dosages was found to be equally good at Lund and at the various local clinics. Although no significant difference in survival was found between patients treated with carboplatin and cyclophosphamide according to this model and patients treated with cisplatin combined with doxorubicin or epirubicin (P = 0.42), the former protocol is more appropriate for use in the out-patient clinic.
|
|